Cue Biopharma Posts $50M Third-Quarter Loss
CUE has more than doubled off its 52-week low of $4.971.
Summary
Cue Biopharma reported a $50M loss for its third quarter, a heavy burn for a company with a roughly $102M market cap. The red ink lands after a strong stretch: positive Phase 2 topline data for CUE-221 in chronic spontaneous urticaria in September sent shares up 51% premarket to $56.00, and the stock now sits at $14.10. Cash is the pressure point — the last 10-Q showed $17.4M on hand against a $153.1M net loss, backstopped by a July private placement that raised $49.8M and a $300M shelf with a $12.67M ATM. The loss figure alone doesn't say whether it includes non-cash items like warrant or milestone charges, so the 10-Q detail matters more than the headline number.
At the time of this announcement, CUE was trading at $14.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.4M. The 52-week trading range was $4.97 to $45.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.